 Outlook Therapeutics Inc NASDAQ:OTLK said it has entered into securities purchase agreements with existing institutional and accredited investors for a registered direct offering priced at-the-market under Nasdaq rules. The offering is for the purchase and sale of 28,460,831 shares of common stock at a purchase price of 0.8784 per share, resulting in aggregate gross proceeds of approximately 25.0 million. 